Clinical Trials in Massachusetts

Showing 11061-11080 of 15,316 trials

TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

NCT00451321

The purpose of this study is to optimize several multi-dose regimens of otelixizumab, determine the highest biologically active dose, evaluate biomarkers and surrogates of efficacy, and to evaluate the effects of each multi-dose regimen of otelixizumab against standard safety and efficacy parameters.

Diabetes Mellitus, Type 1

GlaxoSmithKline88 participantsStarted Jul 2006

Birmingham, Alabama, United States • Walnut Creek, California, United States • Aurora, Colorado, United States +14 more locations

TERMINATEDPhase 426 miles

Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion

NCT01246011

Heparin/Platelet Factor 4 (PF4) antibody testing will be performed in subjects who have just undergone coronary artery bypass grafting (CABG) surgery. 30 subjects with a positive antibody result and no signs or symptoms of Heparin Induced Thrombocytopenia (HIT) will be randomized to receive argatroban and warfarin. 30 subjects with a positive antibody result and no signs or symptoms of HIT will be randomized to receive no treatment. 30 subjects with a negative antibody result will also be followed in the study. All subjects will have a cardiac CT scan at about 30 days post surgery to measure the patency of their coronary artery bypass vein grafts. This study will evaluate if treating patients who have heparin PF4 antibodies post-CABG with argatroban and warfarin has any effect on the short-term patency of coronary artery bypass vein grafts.

Coronary Artery Bypass Graft SurgeryPresence of Heparin/Platelet Factor 4 Antibody

Massachusetts General Hospital9 participantsStarted Nov 2010

Boston, Massachusetts, United States

TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion

Find Trials by Condition in Massachusetts

Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Integration of Continuous Glucose Monitoring Into a BiHormonal Closed-Loop Artificial Pancreas

Improving Functional Capacity in Fontan Patients Through Inspiratory Muscle Training

Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.

Extended Follow-Up After Islet Transplantation in T1D

A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis

VEG111485: A QTc Study of Pazopanib

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)

Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents

Natural Evolution of AV Conduction Disorders in Patients Implanted With Cardiac Pacemakers

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects

Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (F.A.M.E.)